The contract reserves the doses on behalf of all European Union member states, between end 2021 to 2023, the statement added. The contract requires that the vaccine production is based in the EU and that essential components are sourced from the EU.
It is expected to make up for more than one-third of Pfizer's full-year sales, with the company in supply talks with several countries for 2022 and beyond.
"Based on what we've seen, we believe that a durable demand for our COVID-19 vaccine - similar to that of the flu vaccines - is a likely outcome," Chief Executive Albert Bourla said in his prepared remarks.
The companies filed a similar request in the United States earlier this month for the vaccine, which is already authorized for use in people from 16 years of age in both the United States and the European Union.
The submissions are based on positive data from a late-stage clinical trial that enrolled 2,260 participants aged 12 to 15, the companies said.